Is Mounjaro Good for Weight Loss? Here's What the Evidence Says

What makes Mounjaro different from other weight-loss medicines?

Most people asking this question have already heard of GLP-1 medicines as a category. Mounjaro sits in that family but adds a second mechanism: it also activates GIP receptors, which play a distinct role in appetite regulation and fat metabolism. That dual action is why, in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine (2025), tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks — the first time two licensed medicines in this class had been compared directly in a large randomised trial.

The SURMOUNT-1 data, which you can read about in NICE's appraisal of tirzepatide (TA1026), showed average reductions of around 20–21% at the highest dose. For someone weighing 100 kg, that's roughly 20 kg. Numbers like that are rare in weight-management medicine. They're also averages (some people lose more, some less) but the direction and scale of the effect is consistent across the trial programme.

If you want to understand how good tirzepatide is for weight loss, including its mechanism and evidence in more depth, the tirzepatide overview page covers both. The short answer to the headline question, though, is: yes, the trial evidence is strong, and it holds up to regulatory scrutiny.

Who responds best to Mounjaro, and who may not be suitable?

If you're reading this page, there's a good chance you've tried other things. That's a reasonable place to be. The people who tend to see the strongest results in trials share a few characteristics: they have a BMI of 30 or above (or 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes), they engage with the accompanying lifestyle changes, and they stay on treatment long enough for the dose titration to reach a maintenance level. Weight loss tends to build gradually over months rather than arriving in the first few weeks.

Not everyone is suitable. People who are pregnant, breastfeeding, or trying to conceive should not take Mounjaro. It is not licensed for under-18s. Certain conditions (including a personal or family history of medullary thyroid carcinoma, or some forms of pancreatitis) require a prescriber to look carefully before approving treatment. The NHS tirzepatide page lists contraindications in plain language and is worth reading before your consultation.

For a closer look at how Mounjaro tends to work across different starting points, the Mounjaro weight-loss results page breaks down the trial figures by dose. If you're specifically wondering about outcomes for men, the Mounjaro for men page addresses that directly.

Side effects: honest picture, not a brochure

Mounjaro's side-effect profile is dominated by the gut. Nausea, loose stools, constipation, indigestion and burping are the most commonly reported effects, and they tend to peak in the early weeks or after a dose increase, then settle. Most people in trials completed treatment without stopping because of side effects, though some did find them persistent enough to stay at a lower maintenance dose rather than titrating to 15 mg.

A small number of people experience more serious effects. Acute pancreatitis is a known but infrequent risk; the symptom to know is severe, persistent stomach pain that spreads to the back. That warrants urgent medical attention, not waiting to see if it passes. Gallbladder problems and signs of dehydration from prolonged vomiting or diarrhoea are also worth taking seriously. You can report any suspected side effect directly through the MHRA Yellow Card scheme.

None of this means Mounjaro is unsafe, it went through extensive clinical review before MHRA licensing and carries a Black Triangle (▼) mark because post-market monitoring is ongoing, as is standard for newer medicines. It means the decision should be made with a prescriber who knows your medical history, not on the strength of a headline figure alone.

The practical side: cost, access and what to expect from treatment

Mounjaro is available on the NHS for qualifying patients under the phased rollout following NICE TA1026, but the eligibility criteria are currently strict (a high BMI alongside multiple weight-related conditions) and waiting times vary considerably by area. Many people who would benefit clinically don't yet qualify under NHS criteria, or don't want to wait.

Private prescribing through a GPhC-registered online pharmacy is the alternative. The cost depends on dose, and it's worth understanding what a legitimate private price actually includes: the clinical consultation, the prescription, the medicine itself, and delivery. If you're comparing prices between providers, our Mounjaro price comparison page explains what to look for and where headline figures often fall short of the full picture.

At nume, a real prescriber reads your consultation the same day. There's no algorithm making that decision. If you're approved as clinically suitable, your pen is dispatched the same day for free next-working-day delivery via DPD in plain packaging. You can read about how we work, or check what our clinical team considers at assessment by visiting the clinical team profile.

Treatment starts at 2.5 mg, a dose designed to let your body adjust, not to produce rapid weight loss from week one. Dose increases happen in steps, guided by your prescriber. Patience with that process tends to pay off, and if you'd like to hear how Mounjaro changed my life from someone who has been through that journey, that account is worth reading before you decide. Ready to find out whether you're a suitable candidate? Check your eligibility with a free consultation.